Mavacamten represents the first agent specifically developed for HCM successfully tested in a Phase III trial, to be registered soon for clinical use, representing a radical change of paradigm in the pharmacological treatment of HCM.

Mavacamten, a Novel Therapeutic Strategy for Obstructive Hypertrophic Cardiomyopathy / Zampieri, Mattia; Argirò, Alessia; Marchi, Alberto; Berteotti, Martina; Targetti, Mattia; Fornaro, Alessandra; Tomberli, Alessia; Stefàno, Pierluigi; Marchionni, Niccolò; Olivotto, Iacopo. - In: CURRENT CARDIOLOGY REPORTS. - ISSN 1523-3782. - ELETTRONICO. - 23:(2021), pp. 71-79. [10.1007/s11886-021-01508-0]

Mavacamten, a Novel Therapeutic Strategy for Obstructive Hypertrophic Cardiomyopathy

Marchi, Alberto;Berteotti, Martina;Targetti, Mattia;Fornaro, Alessandra;Tomberli, Alessia;Stefàno, Pierluigi;Marchionni, Niccolò;Olivotto, Iacopo
2021

Abstract

Mavacamten represents the first agent specifically developed for HCM successfully tested in a Phase III trial, to be registered soon for clinical use, representing a radical change of paradigm in the pharmacological treatment of HCM.
2021
23
71
79
Goal 3: Good health and well-being for people
Zampieri, Mattia; Argirò, Alessia; Marchi, Alberto; Berteotti, Martina; Targetti, Mattia; Fornaro, Alessandra; Tomberli, Alessia; Stefàno, Pierluigi; Marchionni, Niccolò; Olivotto, Iacopo
File in questo prodotto:
File Dimensione Formato  
Zampieri2021_Article_MavacamtenANovelTherapeuticStr.pdf

Accesso chiuso

Tipologia: Pdf editoriale (Version of record)
Licenza: DRM non definito
Dimensione 291.64 kB
Formato Adobe PDF
291.64 kB Adobe PDF   Richiedi una copia

I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificatore per citare o creare un link a questa risorsa: https://hdl.handle.net/2158/1239338
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 19
  • ???jsp.display-item.citation.isi??? 16
social impact